Liquidia Corporation Common Stock vs nVent Electric — how do they compare? Liquidia Corporation Common Stock trades at $34.2 (market cap $3.04B), while nVent Electric trades at $147.1 (market cap $24.72B). The key difference: nVent Electric is far larger — about 8.1× Liquidia Corporation Common Stock's market cap, and nVent Electric pays a 0.55% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and nVent Electric for 14 Days on average.
| LQDA | NVT | |
|---|---|---|
Market Cap | $3.04B | $24.72B |
Volume | 21,111,778 | 2,529,194 |
Sector | Health | Industrials |
52-Week High | $91.03 | $184.34 |
52-Week Low | $22.02 | $94.99 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $2.94B | $26.10B |
Dividend Yield | — | 0.55% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVT trades at $161.47, down 0.8% with a bullish technical outlook and strong institutional support. The company demonstrates robust earnings momentum with three consecutive quarterly beats and a 61% YTD surge driven by AI data-center demand. Recent developments include the $1.75 billion acquisition of Maverick Power and a strategic collaboration with AMD on cooling solutions for AI infrastructure, positioning NVT for continued growth in the expanding data center market.
While NVT's premium valuation (P/E 44.85) and rising competition present risks, strong analyst consensus (85% buy rating) with a $203.86 price target suggests 26% upside potential. The company's expanding AI infrastructure portfolio and solid cash flow generation support long-term growth, though investors should monitor tariff impacts and valuation compression risks in a competitive landscape.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →nVent provides electrical connection and protection solutions, including enclosures, fastening systems, and thermal management products. Its products help support electrical and industrial infrastructure across multiple end markets.
Read more on NVT →